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Phthalates (dialkyl or alkyl/aryl esters of 1,2-
benzenedicarboxylic acid) are a class of widely
used industrial compounds [Agency for Toxic
Substances and Disease Registry (ATSDR)
1995, 1997, 2001, 2002; David et al. 2001].
Many phthalates have various toxicologic and
chemical characteristics and have a spectrum
of industrial applications. Phthalates have
numerous uses as softeners of plastics, solvents
in perfumes, and additives to hairsprays, lubri-
cants, and insect repellents (ATSDR 1995,
1997, 2001, 2002; David et al. 2001). In the
residential construction or automotive indus-
tries, di-(2-ethylhexyl) phthalate (DEHP),
dibutyl phthalate (DBP), and benzylbutyl
phthalate (BzBP) are used in ﬂoorings, paints,
carpet backings, adhesives, wood finishers,
wallpaper, and in polyvinyl chloride (PVC)
products (ATSDR 2002, 2001). Although
phthalates have low volatility, they off-gas and
are present in residential indoor air (Rudel
et al. 2003). DEHP has been found in the air
inside cars at levels from 1 to 34 µg/m3;
indoor residential measurements of DEHP
that were taken in the spring of 2000 ranged
from 0.04 to 0.23 µg/m3 (ATSDR 2002).
People are at risk of exposure because the
phthalates can be absorbed through the skin,
inhaled, ingested, or directly administered to
patients through transfusions or other medical
procedures that use PVC or vinyl medical
devices (ATSDR 1995, 1997, 2001, 2002).
After human exposure, phthalates are rapidly
metabolized to their respective monoesters.
These monoesters are then further metabo-
lized by oxidation and/or glucuronidation to
increase their water solubility, which facilitates
their urinary excretion (ATSDR 1995, 1997,
2001, 2002; Silva et al. 2003a).
Phthalates are a concern in environmental
public health because of the high potential for
human exposure to phthalates and their
demonstrated toxicity in animals. DEHP is a
rodent carcinogen (ATSDR 2002; Huber et al.
1996). DEHP, DBP, BzBP, and several phtha-
late metabolites, such as monobutyl phthalate
(MBP), monobenzyl phthalate (MBzP), and
mono-(2-ethylhexyl) phthalate (MEHP), are
teratogenic in animals (Ema and Miyawaki
2001a, 2001b; Foster et al. 2001; Gray and
Gangolli 1986; Mylchreest et al. 1998; Parks
et al. 2000). Human studies are scarce, but
monoethyl phthalate (MEP) has shown an
association with sperm DNA damage (Duty
et al. 2003).
Understanding human exposure to
phthalates requires information on the con-
centration of these toxicants in the general
population and on the pharmacokinetics of
the phthalates. Because of the ubiquity of the
parent phthalate diesters, human studies using
these as biomarkers have involved highly
exposed populations (Ching et al. 1981;
Dirven et al. 1993; Faouzi et al. 1999;
Mettang et al. 1996; Pollack et al. 1985).
Therefore, we used phthalate monoester
metabolites as markers (Blount et al. 2000a;
Silva et al. 2003b) to assess phthalate exposure
to the general population [Blount et al. 2000b;
Brock et al. 2002; Centers for Disease Control
and Prevention (CDC) 2001, 2003; Hoppin
et al. 2002].
We report nationally representative con-
centrations in the United States of MEP,
MBP, MBzP, and MEHP in individuals
≥ 6 years of age, stratiﬁed by age group, sex,
and race/ethnicity.
Materials and Methods
Survey design. The National Health and
Nutrition Examination Survey (NHANES),
conducted by the National Center for Health
Statistics (NCHS) of the CDC, is an ongoing
survey designed to measure the health and
nutrition status of the civilian noninstitution-
alized U.S. population ≥ 2 months of age
(NCHS 2003). National population estimates
for phthalate metabolites can be derived from
each 2-year cycle of the survey.
The sampling scheme for the NHANES
1999–2000 cycle is a complex multistage area
probability design. Adolescents 12–19 years
of age, adults ≥ 60 years of age, low-income
people, non-Hispanic blacks, and Mexican
Americans were oversampled (i.e., sampled at a
higher proportion than were subjects in other
demographic groups). Data were collected by
household interviews and by standardized
physical examinations conducted in mobile
examination centers. Participation of the human
subjects involved in this research occurred only
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We measured the urinary monoester metabolites of seven commonly used phthalates in approxi-
mately 2,540 samples collected from participants of the National Health and Nutrition Examination
Survey (NHANES), 1999–2000, who were ≥ 6 years of age. We found detectable levels of metabo-
lites monoethyl phthalate (MEP), monobutyl phthalate (MBP), monobenzyl phthalate (MBzP), and
mono-(2-ethylhexyl) phthalate (MEHP) in > 75% of the samples, suggesting widespread exposure in
the United States to diethyl phthalate, dibutyl phthalate or diisobutylphthalate, benzylbutyl phtha-
late, and di-(2-ethylhexyl) phthalate, respectively. We infrequently detected monoisononyl phthalate,
mono-cyclohexyl phthalate, and mono-n-octyl phthalate, suggesting that human exposures to
di-isononyl phthalate, dioctylphthalate, and dicyclohexyl phthalate, respectively, are lower than those
listed above, or the pathways, routes of exposure, or pharmacokinetic factors such as absorption, dis-
tribution, metabolism, and elimination are different. Non-Hispanic blacks had signiﬁcantly higher
concentrations of MEP than did Mexican Americans and non-Hispanic whites. Compared with ado-
lescents and adults, children had signiﬁcantly higher levels of MBP, MBzP, and MEHP but had sig-
niﬁcantly lower concentrations of MEP. Females had signiﬁcantly higher concentrations of MEP
and MBzP than did males, but similar MEHP levels. Of particular interest, females of all ages had
signiﬁcantly higher concentrations of the reproductive toxicant MBP than did males of all ages; how-
ever, women of reproductive age (i.e., 20–39 years of age) had concentrations similar to adolescent
girls and women ≥ 40 years of age. These population data on exposure to phthalates will serve an
important role in public health by helping to set research priorities and by establishing a nationally
representative baseline of exposure with which population levels can be compared. Key words:
mono-(2-ethylhexyl) phthalate, monobenzyl phthalate, monobutyl phthalate, monoethyl phtha-
late, NHANES, phthalate exposure. Environ Health Perspect 112:331–338 (2004).
doi:10.1289/ehp.6723 available via http://dx.doi.org/ [Online 1 December 2003]after informed consent was obtained. Urine
specimens for analyses, including phthalate
metabolites and creatinine concentrations,
were collected from each participant ≥ 6 years
of age during one of three daily examination
periods (0830–1200 hr, 1230–1600 hr,
1630–2000 hr). Sociodemographic information
and medical histories of the survey participants
and their families were collected during the
household interviews (NCHS 2003).
NHANES 1999–2000 was conducted in
26 locations throughout the United States
and included examinations of 9,282 people.
For phthalate monoester measurements, we
analyzed a random one-third subset of samples.
Because the subset was a random selection of
samples from the entire set, the representa-
tional aspect of the survey was maintained
(NCHS 2003).
Laboratory methods. After collection, the
urine specimens were aliquoted and then
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Table 1. GM and selected percentiles of MEP concentrations in urine [in µg/L and µg/g creatinine (95% CI)] for the U.S. population ≥ 6 years of age from NHANES
1999–2000.
Selected percentiles
GM 10th 25th 50th 75th 90th 95th No.
Total 179 (159–201) 28.9 (23.6–34.2) 61.4 (54.0–69.7) 164 (142–192) 450 (378–523) 1,260 (988–1,490) 2,840 (2,020–4,070) 2,536
163 (148–179)a 33.0 (29.1–35.8) 64.7 (57.5–73.5) 141 (132–155) 360 (313–411) 898 (762–1,150) 1,950 (1,460–2,730)
Age group (years)
6–11 91.3 (73.0–114) 27.2 (20.4–35.7) 40.8 (35.9–46.8) 74.7 (50.6–107) 197 (129–259) 378 (290–644) 756 (379–1,070) 328
92.6 (74.2–116) 29.7 (24.9–34.9) 45.6 (33.6–57.7) 79.4 (61.2–121) 165 (124–208) 341 (219–559) 625 (365–784)
12–19 211 (167–266) 32.7 (22.4–50.6) 72.4 (53.6–99.8) 193 (141–256) 558 (432–806) 1,510 (1,060–2,100) 3,260 (1,670–4,100) 752
142 (120–168) 29.8 (27.0–33.5) 50.7 (41.4–57.9) 122 (86.2–168) 361 (279–495) 879 (676–1,260) 1,550 (907–2,030)
≥ 20 190 (168–214) 27.7 (22.0–34.5) 63.3 (56.7–74.9) 180 (154–210) 482 (409–555) 1,340 (1,010–1,660) 3,480 (2,210–5,100) 1,456
179 (161–199) 34.5 (29.1–39.1) 75.6 (66.3–83.6) 154 (139–170) 390 (338–452) 1,010 (810–1,440) 2,170 (1,670–3,490)
20–39 224 (184–272) 31.8 (22.7–47.5) 78.6 (61.4–93.2) 211 (164–263) 526 (434–719) 1,442 (986–2,453) 3,872 (1,893–9,463) 532
178 (147–216) 33.6 (24.6–40.3) 74.9 (58.6–90.6) 154 (132–184) 376 (300–484) 1,149 (673–1,865) 2,661 (1,442–4,071)
≥ 40 161 (148–186) 26.8 (19.2–31.3) 58.7 (48.0–65.1) 152 (129–180) 410 (342–518) 1,125 (892–1,491) 2,746 (1,678–4,560) 924
180 (163–199) 34.8 (28.5–42.3) 76.1 (64.9–84.2) 150 (136–172) 404 (336–476) 996 (803–1,342) 2,064 (1,462–3,348)
Sex
Males 179 (157–204) 28.4 (23.8–35.4) 54.7 (48.3–64.1) 154 (121–191) 523 (400–621) 1,430 (1,150–2,090) 3,480 (2,270–4,330) 1,214
141 (124–159) 27.6 (22.6–33.1) 48.9 (40.3–60.8) 120 (106–138) 324 (268–391) 996 (761–1,420) 1,940 (1,460–2,900)
Females 178 (154–206) 28.0 (21.8–32.1) 65.0 (57.6–80.2) 174 (145–205) 425 (356–482) 977 (825–1,340) 2,230 (1,330–4,100) 1,214
187 (167–209) 42.7 (34.7–51.7) 81.4 (73.4–94.8) 157 (142–182) 377 (333–453) 821 (719–1,150) 1,920 (1,100–3,410)
Race/ethnicity
MA 181 (163–201) 30.2 (25.2–38.1) 66.8 (56.6–77.4) 174 (150–205) 441 (410–510) 1,250 (893–1,410) 1,720 (1,410–2,450) 813
164 (145–186) 36.3 (29.2–41.5) 63.4 (53.6–77.9) 154 (136–175) 382 (323–469) 814 (692–886) 1,330 (1,010–1,860)
NHW 322 (278–373) 56.1 (48.3–73.2) 127 (111–143) 306 (256–350) 789 (588–996) 1,880 (1,340–2,460) 3,600 (2,100–4,900) 603
208 (183–237) 46.7 (38.4–54.7) 86.4 (69.8–108) 196 (164–232) 443 (363–528) 1,030 (762–1,700) 1,880 (1,290–2,450)
NHW 152 (134–173) 27.2 (20.1–31.1) 52.3 (44.6–61.4) 133 (110–157) 366 (312–450) 977 (796–1,340) 2,470 (1,430–4,330) 907
149 (133–167) 31.8 (26.5–34.7) 58.6 (50.7–68.6) 128 (113–139) 313 (249–376) 834 (663–1,200) 1,950 (1,420–3,350)
Abbreviations: MA, Mexican American; NHB, non-Hispanic black; NHW, non-Hispanic white. MEP was detected in all samples. 
aItalic type denotes measure in µg/g creatinine (95% CI).
Table 2. GM and selected percentiles of MBP concentrations in urine [in µg/L and µg/g creatinine (95% CI)] for the U.S. population ≥ 6 years of age from NHANES
1999–2000.
Selected percentiles
GM 10th 25th 50th 75th 90th 95th No. (%)
Total 24.6 (22.7–26.6) 5.70 (4.80–6.40) 12.6 (11.0–14.3) 26.0 (24.2–28.5) 51.6 (46.9–56.1) 98.6 (90.7–114) 149 (126–167) 2,541 (99)
22.4 (21.1–23.8)a 7.74 (6.79–8.63) 12.8 (11.7–14.2) 21.9 (20.3–23.4) 38.9 (36.1–41.1) 68.3 (61.7–74.9) 97.5 (84.4–113)
Age group (years)
6–11 41.4 (35.8–47.8) 15.1 (11.0–16.9) 23.0 (19.1–27.2) 40.0 (33.7–50.3) 75.5 (59.0–94.5) 124 (92.8–166) 163 (114–306) 328 (100)
41.9 (37.2–47.4) 16.7 (10.6–22.0) 27.8 (23.3–32.1) 38.9 (32.5–49.6) 65.7 (54.9–80.0) 107 (80.0–162) 159 (106–196)
12–19 36.0 (31.9–40.5) 11.9 (8.10–14.8) 20.0 (17.3–25.4) 36.1 (31.7–42.3) 67.7 (56.7–76.1) 119 (94.3–146) 165 (133–209) 752 (100)
24.3 (22.0–26.8) 9.80 (7.68–11.5) 15.4 (13.2–17.0) 23.6 (21.6–26.3) 37.6 (32.6–42.2) 62.3 (53.7–72.1) 88.1 (69.6–139)
≥ 20 21.6 (19.7–23.6) 4.70 (4.2–5.9) 10.3 (9.4–11.6) 23.0 (20.7–25.0) 46.1 (39.7–51.3) 95.0 (81.1–107) 142 (118–161) 1,461 (99)
20.4 (19.0–21.9) 7.08 (5.95–8.18) 11.7 (10.9–13.0) 19.5 (18.4–21.0) 34.9 (31.2–38.2) 62.4 (56.0–68.6) 91.0 (78.3–112)
20–39 25.1 (21.8–29.0) 6.2 (4.2–7.7) 12.5 (9.8–15.5) 27.7 (23.6–31.7) 50.4 (42.2–55.7) 98.9 (81.6–114) 126 (110–163) 532 (99)
20.0 (17.9–22.3) 7.71 (5.27–8.83) 12.2 (10.8–14.2) 19.1 (17.5–21.3) 33.7 (29.1–39.5) 56.3 (46.9–69.1) 81.4 (60.8–135)
≥ 40 19.1 (17.1–21.5) 4.3 (3.4–5.1) 9.4 (8.2–10.5) 19.3 (17.0–22.5) 40.4 (33.8–47.9) 84.4 (67.6–107) 145 (119–170) 929 (98)
20.7 (19.2–22.4) 7.06 (5.92–8.27) 11.5 (10.3–12.8) 19.9 (18.1–22.1) 36.4 (31.7–40.1) 66.7 (59.1–76.7) 97.7 (79.4–115)
Sex
Males 22.0 (20.2–24.0) 5.70 (4.70–6.60) 11.3 (9.90–13.0) 23.1 (21.0–25.2) 43.1 (36.9–49.3) 83.9 (71.3–96.2) 115 (96.2–142) 1,215 (99)
17.3 (16.0–18.7) 6.54 (5.70–7.46) 10.2 (9.57–11.3) 17.0 (15.5–18.7) 28.6 (25.8–32.0) 49.1 (42.4–53.9) 63.6 (57.3–76.7)
Females 27.3 (24.4–30.4) 5.80 (4.10–7.60) 13.8 (11.6–16.4) 30.0 (26.1–33.1) 59.5 (52.0–65.6) 119 (100–143) 167 (145–218) 1,326 (98)
28.6 (26.5–30.9) 10.6 (8.54–11.7) 17.3 (15.9–18.6) 28.6 (26.2–30.4) 50.6 (44.9–54.2) 84.3 (73.5–97.6) 131 (98.5–153)
Race/ethnicity
MA 23.4 (20.8–26.4) 5.10 (4.40–6.10) 11.8 (10.1–13.9) 26.3 (23.6–29.2) 48.1 (41.8–54.6) 92.2 (71.9–107) 116 (101–136) 814 (98)
21.2 (18.9–23.9) 6.98 (5.23–8.50) 12.9 (10.2–14.5) 20.0 (18.2–22.8) 40.1 (33.7–44.0) 63–6 (57.6–70.1) 81.6 (73.9–100)
NHB 37.0 (32.5–42.1) 10.3 (8.00–14.4) 22.2 (18.2–24.6) 38.7 (34.5–42.6) 78.2 (63.1–86.7) 117 (104–149) 167 (143–192) 603 (99)
23.9 (21.6–26.4) 8.51 (6.90–9.92) 13.9 (12.4–16.0) 25.0 (20.7–27.9) 42.2 (36.8–49.3) 69.6 (62.6–83.9) 94.4 (76.7–108)
NHW 21.8 (19.8–24.0) 5.00 (4.20–6.30) 10.6 (9.60–12.5) 23.1 (20.4–26.1) 45.9 (39.1–51.6) 90.2 (75.4–102) 138 (112–161) 911 (98)
21.3 (19.6–23.2) 7.16 (6.03–8.54) 12.1 (11.1–13.9) 20.5 (18.9–22.9) 36.4 (32.3–39.6) 67.1 (58.1–74.9) 97.6 (81.4–135)
Abbreviations: MA, Mexican American; NHB, non-Hispanic black; NHW, non-Hispanic white. No. (%) represents sample size and percentage of detection.
aItalic type denotes measure in µg/g creatinine (95% CI).stored cold (2–4°C) or frozen until they were
shipped. Samples were analyzed for creatinine
using a Beckman Synchron AS/ASTRA
clinical analyzer (Beckman Instruments, Inc.,
Brea, CA) at the University of Minnesota
Medical Center. Samples collected for phtha-
late metabolite measurements were shipped on
dry ice to the CDC’s National Center for
Environmental Health. Urine samples were
stored frozen at –20°C until analyzed. The
samples were analyzed by isotope dilution
high-performance liquid chromatography
coupled with tandem mass spectrometry as
previously described (Blount et al. 2000a; Silva
et al. 2003b). Phthalate urinary concentrations
are reported both in micrograms per liter of
urine and in micrograms per gram of urinary
creatinine. Creatinine adjustment was used to
correct for urine dilution (Jackson 1966).
Demographic categories. On the basis of
self-reported data, a composite race/ethnicity
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Table 3. GM and selected percentiles of MBzP concentrations in urine [in µg/L and µg/g creatinine (95% CI)] for the U.S. population ≥ 6 years of age from
NHANES 1999–2000.
Selected percentiles
GM 10th 25th 50th 75th 90th 95th No. (%)
Total 15.3 (14.0–16.8) 2.80 (2.30–3.50) 6.90 (6.00–8.20) 17.0 (15.3–18.6) 35.3 (32.8–38.9) 67.1 (56.8–80.7) 103 (90.3–123) 2,541 (97)
14.0 (13.0–15.0)a 4.41 (3.64–4.75) 7.57 (6.89–8.45) 13.3 (12.7–14.6) 25.1 (23.5–27.0) 50.1 (41.4–59.6) 77.4 (69.2–88.7)
Age group (years)
6–11 39.4 (34.7–44.8) 9.40 (7.20–13.9) 22.1 (17.2–28.1) 40.3 (34.2–48.6) 82.0 (59.9–90.0) 128 (98.1–214) 214 (107–464) 328 (99)
40.0 (34.1–46.9) 12.5 (9.32–18.3) 21.7 (19.4–27.2) 38.4 (30.3–50.6) 73.2 (58.2–89.4) 104 (89.4–142) 142 (99.8–173)
12–19 25.6 (22.7–29.0) 6.30 (5.10–8.10) 13.4 (10.8–15.9) 28.3 (23.0–33.6) 51.1 (43.7–58.5) 87.9 (71.2–106) 125 (100–160) 752 (100)
17.3 (15.5–19.3) 6.01 (5.39–7.09) 10.6 (8.68–12.3) 17.0 (14.9–19.7) 28.3 (24.9–32.3) 49.7 (41.4–61.7) 69.3 (50.1–81.9)
≥ 20 12.4 (11.3–13.8) 2.20 (1.80–2.80) 5.80 (5.10–6.40) 13.8 (12.3–15.3) 28.9 (26.5–31.9) 52.0 (45.3–56.8) 86.3 (61.3–103) 1,461 (96)
11.8 (10.9–12.7) 3.59 (3.16–4.42) 6.67 (6.09–7.46) 12.1 (11.3–12.8) 20.1 (18.5–23.1) 34.3 (30.5–40.8) 57.2 (42.5–73.9)
20–39 15.8 (13.4–18.5) 3.1 (2.2–4.2) 8.4 (5.9–10.3) 17.1 (14.1–19.9) 34.0 (28.1–39.6) 58.4 (49.3–90.8) 98.4 (63.8–140) 532 (99)
12.5 (11.0–14.3) 4.55 (3.21–5.23) 7.49 (6.15–8.83) 12.6 (11.4–13.3) 20.7 (17.7–24.9) 35.0 (28.4–49.4) 61.1 (36.3–81.4)
≥ 40 10.3 (9.1–11.8) 1.9 (1.2–2.4) 4.8 (4.2–5.3) 11.6 (9.8–13.3) 25.2 (21.4–28.0) 45.0 (38.3–52.1) 67.4 (51.0–87.4) 929 (95)
11.2 (10.2–12.3) 3.49 (2.90–4.07) 6.20 (5.86–6.67) 11.6 (10.5–12.6) 19.96 (17.8–23.2) 33.8 (28.6–41.2) 56.8 (36.0–77.4)
Sex
Males 16.2 (14.5–18.0) 3.40 (2.40–4.40) 8.00 (6.00–9.20) 17.7 (15.5–19.4) 35.4 (32.8–38.6) 69.4 (59.9–85.8) 108 (94.0–139) 1,215 (97)
12.7 (11.6–13.9) 3.81 (3.26–4.67) 6.58 (5.94–7.61) 12.3 (11.5–13.1) 23.7 (21.5–26.1) 44.5 (36.6–53.3) 73.5 (57.0–89.4)
Females 14.6 (13.0–16.3) 2.40 (1.90–3.10) 6.10 (5.20–7.60) 16.0 (14.2–19.2) 35.8 (31.0–41.0) 63.7 (54.7–74.1) 103 (86.3–116) 1,326 (97)
15.3 (14.1–16.5) 4.84 (4.38–5.72) 8.73 (7.52–9.63) 14.7 (13.3–16.1) 25.9 (24.1–29.2) 56.4 (41.4–64.3) 80.0 (64.8–99.1)
Race/ethnicity
MA 13.9 (11.9–16.4) 2.40 (1.70–3.50) 6.30 (5.20–7.80) 15.7 (12.1–18.0) 33.0 (26.7–37.2) 67.5 (55.9–80.6) 98.3 (80.6–150) 814 (96)
12.6 (11.2–14.3) 3.49 (3.00–4.21) 6.55 (5.49–7.77) 11.9 (10.7–13.5) 24.1 (20.8–28.7) 46.5 (40.9–54.2) 68.1 (55.2–98.8)
NHB 23.0 (20.0–26.5) 5.10 (3.70–6.40) 12.3 (10.0–13.7) 23.0 (20.0–27.0) 49.3 (40.1–56.1) 94.0 (79.1–130) 138 (115–233) 603 (99)
14.8 (13.0–16.9) 4.93 (3.96–5.88) 7.81 (7.12–8.75) 13.6 (11.7–15.6) 26.9 (21.9–32.4) 55.5 (38.7–77.2) 86.8 (64.4–99.8)
NHW 14.3 (12.7–16.0) 2.50 (1.90–3.20) 6.50 (5.30–8.10) 16.1 (14.3–18.5) 33.9 (30.7–37.5) 58.7 (52.0–71.5) 103 (73.4–116) 911 (97)
14.0 (12.7–15.3) 4.42 (3.52–4.77) 7.66 (6.47–8.75) 13.4 (12.6–15.2) 25.2 (23.2–27.3) 53.3 (38.6–65.6) 77.9 (69.1–90.3)
Abbreviations: MA, Mexican American; NHB, non-Hispanic black; NHW, non-Hispanic white. No. (%) represents sample size and percentage of detection.
aItalic type denotes measure in µg/g creatinine (95% CI).
Table 4. GM and selected percentiles of MEHP concentrations in urine [in µg/L and µg/g creatinine (95% CI)] for the U.S. population ≥ 6 years of age from
NHANES 1999–2000.
Selected percentiles
GM 10th 25th 50th 75th 90th 95th No. (%)
Total 3.43 (3.19–3.69) < LOD 1.20 (< LOD–1.40) 3.20 (2.90–3.50) 7.60 (6.80–8.20) 14.8 (13.6–17.3) 23.8 (19.2–28.6) 2,541 (78)
3.12 (2.92–3.35)a < LOD 1.52 (1.37–1.69) 3.08 (2.81–3.31) 5.88 (5.38–6.27) 10.8 (9.47–12.9) 18.5 (14.0–23.9)
Age group (years)
6–11 5.12 (4.25–6.16) < LOD 2.40 (1.80–3.10) 4.90 (3.80–5.50) 11.1 (7.70–13.7) 19.0 (13.7–36.1) 34.5 (14.7–130) 328 (87)
5.19 (4.17–6.45) < LOD 2.56 (2.05–3.33) 5.37 (4.00–6.29) 9.11 (7.51–12.1) 21.6 (11.6–41.9) 41.9 (13.5–86.2)
12–19 3.75 (3.30–4.27) < LOD 1.60 (1.30–1.80) 3.70 (2.90–4.50) 8.10 (6.30–9.60) 15.0 (11.5–20.2) 22.8 (19.5–26.3) 752 (84)
2.53 (2.21–2.89) < LOD 1.22 (1.03–1.46) 2.31 (2.11–2.60) 5.83 (4.42–6.27) 9.63 (7.78–11.3) 12.1 (11.0–17.3)
≥ 20 3.21 (2.95–3.49) < LOD < LOD 3.00 (2.60–3.30) 7.20 (6.30–8.10) 14.2 (12.2–16.5) 22.4 (16.8–27.8) 1,461 (76)
3.03 (2.80–3.29) < LOD < LOD 2.98 (2.72–3.26) 5.55 (4.90–6.04) 10.0 (8.60–12.9) 17.5 (13.4–22.1)
20–39 4.15 (3.65–4.72) < LOD 1.40 (1.2–1.9) 3.90 (3.3–4.6) 9.4 (8.0–11.5) 17.5 (14.0–23.7) 27.3 (19.7–42.5) 532 (82)
3.30 (2.93–3.712) < LOD 1.52 (1.27–1.91) 3.25 (2.68–3.63) 6.21 (5.29–7.08) 13.3 (9.77–15.4) 20.9 (14.7–28.4)
≥ 40 2.62 (2.38–2.89) < LOD < LOD 2.3 (2.0–2.7) 5.3 (4.7–6.3) 11.3 (8.7–13.6) 16.8 (13.6–22.7) 929 (70)
2.84 (2.59–3.10) < LOD 1.49 (1.33–1.67) 2.82 (2.58–3.10) 4.91 (4.45–5.40) 8.75 (7.3–10.2) 12.9 (10.0–21.6)
Sex
Males 3.68 (3.26–4.15) < LOD 1.40 (1.20–1.80) 3.40 (2.80–4.10) 8.00 (6.80–9.10) 16.0 (13.8–20.2) 25.3 (18.3–38.3) 1,215 (81)
2.89 (2.58–3.24) < LOD 1.33 (1.19–1.52) 2.76 (2.37–3.18) 5.58 (4.67–6.11) 10.3 (8.90–13.5) 21.6 (13.3–28.4)
Females 3.21 (2.93–3.51) < LOD 1.20 (< LOD–1.40) 3.00 (2.70–3.50) 7.00 (5.90–8.10) 13.5 (11.4–15.2) 21.6 (17.2–26.0) 1,326 (76)
3.36 (3.12–3.63) < LOD 1.82 (1.63–1.99) 3.33 (3.00–3.66) 6.15 (5.55–6.76) 11.1 (9.33–13.5) 16.3 (12.9–23.7)
Race/ethnicity
MA 3.49 (3.13–3.88) < LOD 1.50 (< LOD–1.70) 3.50 (3.00–3.70) 7.00 (5.90–8.60) 13.3 (10.7–19.1) 23.9 (16.4–29.3) 814 (80)
3.16 (2.77–3.60) < LOD 1.54 (1.36–1.79) 3.15 (2.62–3.74) 5.88 (4.92–7.20) 11.6 (10.0–12.6) 15.7 (12.6–23.1)
NHB 4.82 (4.07–5.71) < LOD 2.50 (1.70–3.00) 5.10 (4.10–5.90) 9.40 (7.80–11.2) 19.5 (14.6–24.5) 29.2 (19.5–39.3) 603 (879)
3.11 (2.68–3.61) < LOD 1.68 (1.31–1.98) 3.13 (2.62–3.37) 5.84 (4.66–7.06) 10.2 (8.77–13.6) 18.4 (11.8–35.2)
NHW 3.16 (2.89–3.46) < LOD < LOD 2.70 (2.50–3.10) 7.30 (6.30–8.20) 14.4 (12.2–16.6) 22.4 (16.5–29.3) 911 (75)
3.09 (2.80–3.41) < LOD < LOD 3.08 (2.67–3.48) 5.87 (5.14–6.67) 10.6 (8.74–13.7) 20.0 (13.1–27.7)
Abbreviations: MA, Mexican American; NHB, non-Hispanic black; NHW, non-Hispanic white. LOD is 1.2 µg/L. No. (%) represents sample size and percentage of detection.
aItalic type denotes measure in µg/g creatinine (95% CI).variable helped deﬁne three major race/ethnic-
ity groups: non-Hispanic blacks, non-Hispanic
whites, and Mexican Americans. Persons not
defined by these three race/ethnicity groups
were included only in the total population
estimate. During household interviews, age was
reported in years at the last birthday. Age cate-
gories were 6–11 years (children), 12–19 years
(adolescents), and ≥ 20 years of age (adults).
For analyses that would allow comparison with
previously reported data, the adult age category
was further broken down to 20–39 years, to
represent reproductive age in women, and
≥ 40 years.
Statistical analysis. Statistical analyses
were performed using the statistical software
packages SAS (SAS Institute, Cary, NC) and
SUDAAN (release 8.0; Research Triangle
Institute, Research Triangle Park, NC).
SUDAAN incorporates the sample population
weights and calculates variance estimates that
account for the complex design of NHANES.
The survey-specific sample weights were
designed speciﬁcally for the one-third subset of
the full survey. Parametric statistics were com-
puted only for analytes for which the frequency
of detection was ≥ 60%.
We calculated the geometric means (GMs)
and distribution percentiles for both the vol-
ume-based and creatinine-corrected concentra-
tions using the survey sampling weights, which
take into account the unequal selection proba-
bilities caused by the cluster design and the
planned oversampling of certain subgroups.
The analytical limits of detection (LODs) were
MEP, 1.0 µg/L; MBP, 0.6 µg/L; MBzP,
0.8 µg/L; MEHP, 1.2 µg/L; mono-cyclohexyl
phthalate (MCHP), 0.7 µg/L; mono-n-octyl
phthalate (MOP), 0.9 µg/L; and mono-3-
methyl-5-dimethylhexyl phthalate [mono-
isononyl phthalate (MINP)], 0.8 µg/L. For
concentrations below the LOD, a value equal
to the LOD divided by the square root of 2
was used (Hornung and Reed 1990).
We used an analysis of covariance model to
study the effects of several covariates (i.e., sex,
race/ethnicity, age, and urinary creatinine) on
the log-transformed urinary phthalate metabo-
lite concentrations. This model enabled us to
compare the expected least square geometric
mean (LSGM) phthalate metabolite levels for
selected demographic groups (e.g., male vs.
female), which were adjusted statistically so
that subjects had comparable levels of all other
covariates. We compared and contrasted the
LSGMs of demographic groups using only the
volume-based concentrations, because creati-
nine was included as a covariate. The LSGMs
normalize phthalate metabolite levels across
demographic groups by standardizing for dif-
ferences in the other covariates. We obtained
similar results for GMs of creatinine-corrected
concentrations and for LSGMs. We also deter-
mined the weighted correlations among the
phthalate metabolites by using a weighted
regression model. The analyses were considered
to be statistically significant when p < 0.05,
and were considered to be nominally or mar-
ginally signiﬁcant when p > 0.05 but p < 0.1.
Cotinine concentrations of 0.1 µg/L defined
the smoking status for LSGM determinations
when an interaction existed between phthalate
levels and smoking status. When there was an
interaction between age group and smoking
status, we analyzed only nonsmokers because
the number of smokers was relatively small.
Results
The distribution of the four most commonly
detected phthalate metabolites in the approxi-
mately 2,540 NHANES 1999–2000 samples
analyzed are presented in Tables 1–4 and in
Figure 1. The creatinine-adjusted GMs for each
demographic group are shown in Figure 2.
Levels of MEP in the highest concentrations
were detected in all of the samples tested. We
detected MBP in 99% of the samples, MBzP in
97% of the samples, and MEHP in 78% of the
samples tested; however, we found MCHP,
MOP, and MINP in < 16% of the samples.
MEP urinary levels by age, sex, and
race/ethnicity. The MEP levels by age, sex,
and race/ethnicity are displayed in Table 1
and in Figures 2 and 3. We found that MEP
creatinine-corrected levels were higher in
adults and adolescents than in children. They
also were higher in females than in males, and
were higher in non-Hispanic blacks compared
with non-Hispanic whites and Mexican
Americans. The LSGM concentrations of
MEP (Table 5) were significantly lower in
children than in adolescents (p = 0.01753) and
adults (p < 0.0001); the difference between
adult and adolescent LSGM concentrations
was only marginally signiﬁcant (p = 0.09296;
Table 6). Females had significantly higher
LSGM concentrations of MEP than did males
(p = 0.002). Non-Hispanic blacks had signiﬁ-
cantly higher LSGM concentrations than did
both non-Hispanic whites (p = 0.00049) and
Mexican Americans (p = 0.01788). Mexican
Americans had higher concentrations than did
non-Hispanic whites, which were marginally
signiﬁcant (p = 0.05528; Table 6).
There were signiﬁcant interactions between
age and race/ethnicity (p = 0.0244) and
between sex and creatinine (p = 0.0009).
Therefore, age groups were compared sepa-
rately within each race/ethnicity, and males
and females were compared at a common crea-
tinine level of 130.4 mg/dL. Nonsmoking
females had signiﬁcantly higher LSGM MEP
concentrations (204.7 µg/L) than did males
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Figure 1. Population distributions of MEP, MBP,
MBzP, and MEHP in urine. Circles indicate 5th and
95th percentiles, horizontal bars inside the box indi-
cate the medians, whiskers below and above are
10th and 90th percentiles, and box boundaries are
25th and 75th percentiles. The lower MEHP concen-
trations compared with MEP, MBP, and MBzP may
be due to lower exposure or different pathways,
routes of exposure, or pharmacokinetic factors.
Figure 2. GM urinary concentrations (in µg/g creati-
nine) of MEP, MBP, MBzP, and MEHP in the U.S.
general population ≥ 6 years of age. Levels of
MEHP, MBzP, and MBP were higher in children
than in adolescents and adults. Women had higher
levels of MEP, MBzP, and MBP than did males but
similar levels of MEHP. Non-Hispanic blacks had
higher levels of MEP than did the other race/
ethnicity groups.
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Figure 3. Distribution of MEP levels in urine by age
and race/ethnicity (only nonsmokers were used in
the LSGM estimation); error bars represent upper
95% CIs. Non-Hispanic blacks had the highest MEP
levels. Non-Hispanic black adolescents and adults
had higher levels than did non-Hispanic whites and
Mexican Americans of the same age group; how-
ever, the differences were not signiﬁcant. MEP lev-
els in non-Hispanic black children were statistically
higher than in non-Hispanic white (p = 0.00569) and
Mexican American (p = 0.00035) children.
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Mexican Americans
Non-Hispanic blacks
Non-Hispanic whites(149.5 µg/L; p = 0.01354). Non-Hispanic
blacks had the highest LSGM MEP levels,
and adults had higher levels than did adoles-
cents and children (Figure 3). Among non-
smoking non-Hispanic blacks, the LSGM
MEP concentrations in adults (243.6 µg/L)
were significantly higher than in adolescents
(167.1 µg/L; p = 0.03941) and higher but
not significantly higher than in children
(169.3 µg/L; p = 0.08233). The differences
between children and adolescents were not
statistically significant. Among nonsmoking
non-Hispanic whites, the LSGM concen-
trations of MEP in children (91.6 µg/L)
were significantly lower than in adolescents
(148.0 µg/L, p = 0.03295) and adults
(178.8 µg/L; p < 0.00001); the difference was
not signiﬁcant between adolescents and adults
(p = 0.25460). Among nonsmoking Mexican
Americans, the LSGM concentrations of MEP
(Figure 3) in adults (219.6 µg/L) were signiﬁ-
cantly higher than in children (86.0 µg/L;
p < 0.00001) and adolescents (152.6 µg/L;
p = 0.00676). Mexican-American adolescents
had signiﬁcantly higher LSGM MEP concen-
trations than did Mexican-American children
(p = 0.00021).
MBP urinary levels by age, sex, and
race/ethnicity. The MBP levels by age, sex and
race/ethnicity are exhibited in Table 2 and
Figure 2. We found that MBP creatinine-
corrected levels were higher in children than in
adolescents and adults, were higher in females
than in males, and were similar among the
three race/ethnicity groups. The LSGM MBP
concentrations (Tables 5 and 6) in children
were significantly higher than in adolescents
(p < 0.00001) and adults (p < 0.00001).
Adolescents had signiﬁcantly higher concentra-
tions than adults (p = 0.00147). Furthermore,
females had signiﬁcantly higher concentrations
of MBP than did males (p < 0.00001). Women
of reproductive age (20–39 years of age) had
LSGM MBP concentrations (24.4 µg/L) similar
to those of adolescents (34.7 µg/L) and women
≥ 40 years of age (28.6 µg/L; Figure 4). We
observed no signiﬁcant differences among the
race/ethnicity groups. Also, we observed no sig-
nificant interactions between creatinine, age
groups, sexes, or race/ethnicities.
MBzP urinary levels by age, sex, and
race/ethnicity. The MBzP levels by age, sex,
and race/ethnicity are displayed in Table 3
and Figures 2 and 5. We found that MBzP
creatinine-corrected levels were higher in chil-
dren than in adolescents and adults. They also
were higher in females than in males and were
similar for non-Hispanic whites and non-
Hispanic blacks, but were slightly higher in
each of these groups than in the Mexican-
American group. Children had significantly
higher LSGM concentrations of MBzP than
did adolescents (p < 0.00001) and adults
(p < 0.00001; Tables 5 and 6). Similarly, ado-
lescents had signiﬁcantly higher LSGM con-
centrations of MBzP than did adults. Females
had signiﬁcantly higher LSGM MBzP concen-
trations than did males (p = 0.00042). Non-
Hispanic whites had significantly higher
LSGM MBzP concentrations than did
Mexican Americans (p = 0.04273). The differ-
ences were not statistically signiﬁcant between
non-Hispanic blacks and both groups of non-
Hispanic whites and Mexican Americans
(Table 6).
Signiﬁcant interactions existed between age
and sex (p = 0.0003), between sex and creati-
nine (p = 0.0033), between race/ethnicity and
serum cotinine (p = 0.0397), and between age
and creatinine (p = 0.0198). Because of these
interactions, estimates and significance tests
were performed within selected groups. LSGM
concentrations of MBzP (Figure 5) in female
children (46.3 µg/L) were signiﬁcantly higher
than in adult women (14.5 µg/L; p < 0.00001)
and adolescent girls (18.6 µg/L; p < 0.00001);
adolescent girls had signiﬁcantly higher levels
than did adult women (p = 0.01454).
Similarly, the LSGM concentrations of MBzP
(Figure 5) in male children (51.4 µg/L) were
significantly higher than in adult men
(9.9 µg/L; p < 0.00001) and adolescent boys
(23.4 µg/L; p = 0.00006); adolescent boys had
signiﬁcantly higher levels than did adult men
(p < 0.00001). Children, regardless of sex, had
similar MBzP LSGM levels (p = 0.46875). In
contrast, adolescent boys and adult men had
significantly higher (p = 0.01814) and lower
(p = 0.00127) MBzP LSGM levels, respec-
tively, than did females within the same age
group (Figure 5).
MEHP urinary levels by age, sex, and
race/ethnicity. The MEHP levels by age, sex,
and race/ethnicity are exhibited in Table 4 and
Figure 2. We found that MEHP creatinine-
corrected levels were higher in children than in
adolescents and adults, were higher in females
than in males, and were similar among the
three race/ethnicity groups. The model-
estimated LSGMs of MEHP (Table 5) in chil-
dren were signiﬁcantly higher than in adoles-
cents (p = 0.0001) and adults (p = 0.00001).
We observed no statistically signiﬁcant differ-
ences among sex and race/ethnicity groups
(Table 6).
Discussion
We measured urinary levels of seven phthalate
monoesters in approximately 2,540 NHANES
1999–2000 samples. The detection of MEP,
MBP, and MBzP in > 97% and MEHP in
> 75% of the samples demonstrates wide-
spread exposure to some phthalates across the
U.S. population. We infrequently detected
MINP, MOP, and MCHP.
Despite the fact DEHP is the most widely
used and produced phthalate, we found
higher urinary concentrations of MEP,
MBP, and MBzP than of MEHP. The lower
MEHP concentrations may be due to lower
exposure, absorption, metabolism, or excre-
tion. Metabolism studies of DEHP show that
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Table 5. LSGM concentrations of MEP, MBP, MBzP, and MEHP in various demographic groups.
Ethnicity
Phthalate Mexican Non-Hispanic Non-Hispanic Age group Sex
metabolite Americans blacks whites Children Adolescents Adults Female Male
MEP 191.9 237.8 162.1 105.2 151.6 187.4 194.4 152.6
MBP 23.0 24.6 23.5 52.2 26.9 21.0 29.8 18.5
MBzP 13.1 14.7 15.5 51.5 19.6 12.5 16.9 13.5
MEHP 3.4 3.6 3.3 5.3 2.9 3.2 3.5 3.2
Table 6. Observed statistical significance values for differences between LSGM concentrations of MEP,
MBP, MBzP, and MEHP for various demographic groups.
Difference MEP MBP MBzP MEHP
MA–NHB 0.01788 0.43659 0.25625 0.26329
NHW–NHB 0.00049 0.59064 0.56203 0.26329
MA–NHW 0.05528 0.68315 0.04273 0.47333
Children–adolescents 0.01753 < 0.00001 < 0.00001 0.0001
Adult–adolescents 0.09296 0.00147 < 0.00001 0.31049
Adults–children < 0.00001 < 0.00001 < 0.00001 0.00001
Female–male 0.002 < 0.00001 0.00042 0.39283
Abbreviations: MA, Mexican Americans; NHB, non-Hispanic blacks; NHW, non-Hispanic whites.
Figure 4. LSGM MBP levels in male and female non-
smoking participants in NHANES 1999–2000. Error
bars indicate lower and upper 95% CIs. Females
had higher concentrations of MBP than did males,
but women of reproductive age had concentrations
(24.4 µg/L) similar to those of adolescent girls
(34.7 µg/L) and women ≥ 40 years of age (28.6 µg/L).
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6–11 12–19 20–39 ≥ 40MEHP undergoes further oxidative metabo-
lism to produce additional metabolites
(ATSDR 2002). Recent studies suggest that
the urinary concentrations of two of these
oxidative metabolites, mono-(2-ethyl-5-oxo-
hexyl) phthalate and mono-(2-ethyl-5-hydrox-
yhexyl) phthalate are several-fold higher than
those for MEHP (Barr et al. 2003; Koch et al.
2003b). Therefore, the relatively low concen-
trations of MEHP may result, at least in part,
from alternative metabolic pathways. A similar
metabolism may be important for other long-
alkyl-chain phthalates such as dioctyl phthalate
(ATSDR 1997) and di-isononyl phthalate
(McKee et al. 2002) and might explain the
lower frequency and magnitude of detection of
their respective monoesters compared with the
monoesters of short-alkyl-chain phthalates
(e.g., MEP, MBP). The low levels of MCHP
found in this population may be due to low
exposure to dicyclohexyl phthalate (DCHP),
because DCHP is used infrequently in the
United States.
The high levels of MEP across the popula-
tion are most likely associated with the everyday
use of consumer products that commonly
contain diethyl phthalate (DEP; ATSDR
1995), such as detergents, soaps, cosmetics,
shampoo, and perfumes. Furthermore, the
higher concentrations of MEP in adults and
adolescents than in children are consistent
with the known behavioral uses of phthalate-
containing consumer products (e.g., adults are
more likely to use cosmetics than are children).
Concentrations of MEP were highly dependent
on both sex and race/ethnicity (Tables 1 and 5).
The fact that women had higher concentrations
of MEP than did men was most likely attribut-
able to women’s increased use of personal care
products, such as hair care products, cosmetics,
and perfumes. Non-Hispanic black children
had LSGM MEP concentrations nearly double
those for non-Hispanic black adolescents and
adults, and non-Hispanic blacks had much
higher MEP concentrations than did the other
two race/ethnicity groups for all ages (Figure 3).
We speculate that these differences may be due
to increased, continuous, or prolonged use of
beauty and hair care products speciﬁcally mar-
keted for this population, often beginning at a
young age (Figure 3).
We found that the concentrations of
MBzP and MBP were highly correlated
(Pearson correlation coefficient R = 0.62,
p < 0.0001). BzBP, the parent phthalate that
produces MBzP, can also metabolize to
MBP; < 10% of the total BzBP in humans is
metabolized to MBP (Anderson et al. 2001).
Furthermore, we observed signiﬁcant correla-
tions between the concentrations of MBP
and both MEP (R = 0.427, p < 0.0001) and
MEHP (R = 0.371, p < 0.0001). These ﬁnd-
ings suggest a possible common source of
exposure for the three parent phthalates;
however, the nature of the source is not as
apparent as it is for MBzP and MBP.
We observed statistically significant
(p < 0.01) variations in the population distribu-
tions of MEP, MBP, and MEHP depending
on the time of sample collection. However,
MBzP concentrations did not change signiﬁ-
cantly. The LSGM concentration of MEP was
highest in the midday collection, and the
LSGM concentrations of MBP, MBzP, and
MEHP were highest in the evening collection
(Figure 6). These differences and the non-
persistent nature of phthalates may reﬂect dif-
ferences in exposure at different times of the
day. For example, a high occurrence of showers
and use of personal care products containing
DEP in the morning may result in elevated
MEP levels in the midday collection samples
compared with other collection periods.
Similarly, increased contacts with vinyl prod-
ucts such as car seat covers and ﬂoor tiles during
daytime may result in elevated MEHP levels in
the evening collection samples.
We found that the levels of MEHP,
MBzP, and MBP were higher in children than
in adolescents and adults (Figure 2). The
LSGMs of each of these analytes in children
were nearly double those for adolescents and
adults (Table 5), suggesting that children have
higher levels of exposure to several phthalates.
These data are of particular concern because
of the known animal toxicity and/or carcino-
genicity of DBP, DEHP, and their monoester
metabolites (ATSDR 2001, 2002), although at
concentrations much higher than those found
in this population and because of the increased
vulnerability of children. The higher exposure
of children to these chemicals may be reason-
ably explained because of their higher food
consumption and air inhalation in relation to
their weight compared with those of adoles-
cents or adults. In addition, children typically
spend more time indoors, and some toys may
contain high concentrations of plasticizers.
However, the observed differences could be
related to other variables, such as differences in
absorption, distribution, metabolism, or excre-
tion of these phthalates. Nevertheless, our
ﬁndings highlight the need for additional toxi-
cokinetic information on phthalates, especially
in children, and the need for epidemiologic
studies to target health outcomes related to
phthalate exposures in children.
We previously reported phthalate mono-
ester concentrations in a convenience group of
289 samples from the NHANES III callback
cohort (Blount et al. 2000b). NHANES III
(1988–1994) was designed as a nationally
representative survey, but the environmental
component, known as the callback cohort
(composed of ~1,000 adults who agreed to have
additional blood and urine samples taken) was
not. Although each demographic group had
some representation in the callback cohort, no
rigorous sample design and no sample weights
were used in analyzing the resulting data. The
frequencies of detection of the phthalate
monoesters were similar among NHANES III
and NHANES 1999–2000. However, the
GMs and medians of the three most frequently
detected phthalate metabolites, MEP, MBP,
and MBzP, were almost 2-fold lower in the
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Figure 5. LSGM MBzP levels in male and female
nonsmoking participants in NHANES 1999–2000.
Error bars indicate lower and upper 95% CIs.
Children had the highest levels: levels in female chil-
dren were signiﬁcantly higher than in adult women
(p < 0.00001) and adolescent girls (p < 0.00001); simi-
larly, the concentrations in male children were sig-
niﬁcantly higher than in adult men (p < 0.00001) and
adolescent boys (p = 0.00006).
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)NHANES 1999–2000 population than in the
NHANES III study population, whereas the
MEHP concentrations remained essentially
constant. These findings may be due to
reduced exposures or may reflect differences
among sample populations. Compared with
the NHANES III study population (Blount
et al. 2000b), women of reproductive age
(20–39 years of age) had concentrations of
MBP similar to those of women 40 or more
years of age in the NHANES 1999–2000
population (Figure 4). These findings are
important because DBP is a reproductive
toxicant; however, women still continue to
have higher MBP concentrations than do
men. The increased levels of MBP among
women 20 to 39 years of age observed in the
small subset of NHANES III samples is likely
related to the small sample size and nonrepre-
sentative nature of the sampling (Blount et al.
2000b). However, it is possible that a true
decrease in exposure to DBP for women in
this age group may have occurred since the
NHANES III sampling. Although the two
data sets are not directly comparable for
establishing exposure trends over time, the
NHANES III data provided useful exposure
information to help focus research efforts.
The phthalate monoester data in speciﬁc
study populations reported in the literature
are limited. Hoppin et al. (2002) evaluated
the temporal variability of urinary phthalate
monoester concentrations in two consecutive
first morning voids from 46 African-American
women in the Washington, DC, area that
were collected during 1996–1997. The
authors reported frequent detection of MEP,
MBzP, MBP, and MEHP as well as reason-
ably stable concentrations between the 2 days.
The median concentrations of MEP (211 µg/L)
were similar to our NHANES 1999–2000
data even compared with data from all indi-
vidual demographic categories that applied
(i.e., adults, women, non-Hispanic blacks).
However, the median concentrations of MBzP
(31 µg/L), MBP (52 µg/L), and MEHP
(7.3 µg/L) in the 46 African-American women
were consistently 1.5–2 times higher than the
NHANES 1999–2000 data, regardless of the
demographic category used for comparison.
In a similar study conducted in New York
City, the same monoester metabolites were
frequently detected in 25 urine samples col-
lected from pregnant African-American and
Dominican women (Adibi et al. 2003). The
median MBzP concentration (12.1 µg/g crea-
tinine) of this group was similar to that meas-
ured here for several demographic groups,
including adults, women, non-Hispanic
blacks, and Mexican Americans. Also, median
concentrations of MEP (236 µg/L) and
MEHP (4.6 µg/L) were somewhat higher than
for the NHANES 1999–2000 population
groups. The median concentration of MBP
(42.6 µg/L) was 1.5–2 times higher than the
NHANES 1999–2000 levels, both collectively
and compared with the demographic groups.
Because reproductive toxicity has been
demonstrated in pregnant rodents exposed to
high doses of DBP, this population should
be studied further to evaluate any associated
health end points.
Phthalate monoester concentrations also
have been measured in 168 men, most of
whom were non-Hispanic whites, to determine
if a relation existed between sperm DNA dam-
age and phthalate exposure (Duty et al. 2003).
The speciﬁc gravity-adjusted GM concentra-
tions of MEP (187 µg/L) and MBP (18.2 µg/L)
of these men were similar to those of the adults,
men, and non-Hispanic whites in our study
population. The GM MBzP concentration in
the 168 men was about half of that found in
the NHANES 1999–2000 population, but the
MEHP concentrations were about double of
those we found for our total population and the
relevant demographic groups.
In another study, phthalate monoester con-
centrations were measured in 19 toddlers
12–18 months of age in Imperial Valley,
California (Brock et al. 2002). Similar to results
of other studies, the metabolites predominantly
detected were MEP, MBP, MBzP, and MEHP.
Although a comparable age group was not
included in the NHANES 1999–2000 popula-
tion, we compared these 19 toddler metabolite
concentrations with those of children 6–11
years of age in NHANES 1999–2000. The
unadjusted mean concentrations of MEP and
MBP were approximately two and three times
higher, respectively, than the GM concentra-
tions in NHANES 1999–2000, whereas the
mean concentrations of MBzP and MEHP
were similar.
A recent study has reported the levels of
several phthalate monoesters (including MEP,
MBP, and MEHP) in eight nonoccupationally
exposed individuals in Germany (Koch et al.
2003a). The mean levels of MEP (1,000 µg/L),
MEHP (8.87 µg/L), and MBP (36.5 µg/L)
were signiﬁcantly higher than the levels found
in the NHANES 1999–2000 population, but
the MBzP levels (7.2 µg/L) were about half the
value found in our present study. The same
group of investigators also measured the con-
centrations of the same phthalate metabolites in
the ﬁrst morning voids, which were collected in
April 2002, from 53 females and 32 males,
7–64 years of age, who live in southern
Germany (Koch et al. 2003b). Similar to the
results for the NHANES 1999–2000 popu-
lation, females had higher creatinine-adjusted
urinary levels of MEP, MBP, MBzP, and
MEHP than did males. These data suggest
similar sex-related differences in exposure to
phthalates both in the United States and in
Germany. However, the median levels of MBP
(157 µg/g creatinine) were 8-fold higher and
the median levels of MEHP (9.2 µg/g creati-
nine) were 3-fold higher in the German popu-
lation than in the NHANES 1999–2000
population. Concentrations of MEP (73.3 µg/g
creatinine) were about half those found in
NHANES 1999–2000, but levels of MBzP
(17.2 µg/g creatinine) were similar. These
data suggest that differences in the exposure
to phthalates may exist geographically. Also,
the varying amounts of phthalates used and
sampling times (e.g., first morning voids vs.
non-ﬁrst morning voids, seasonal vs. through-
out-the-year collection) may account for the
observed differences in the levels of urinary
phthalates.
Conclusions
We report the first nationally representative
population-based phthalate monoester con-
centrations for selected demographic groups
in the United States. These data can be used
with future 2-year surveys to evaluate trends
in phthalate exposure. Consistent with our
previous results, we found that exposure to
phthalates in the United States is widespread.
We found measurable concentrations of
MEP, MBP, and MBzP in > 97% of the sam-
ples tested but found three other metabolites
(MCHP, MOP, and MINP) in < 20% of the
samples tested. In addition, we saw signiﬁcant
differences in metabolite concentrations
across the demographic groups. Children
6–12 years of age had higher concentrations
of MBP, MBzP, and MEHP, whereas adults
had higher concentrations of MEP than did
children. Non-Hispanic blacks had signifi-
cantly higher concentrations of MEP than did
other race/ethnicity groups. Females had
higher concentrations of MBP, the metabolite
of the reproductive toxicant DBP, than did
males; however, women of reproductive age
had concentrations of MBP similar to those
of women ≥ 40 years of age. Collectively,
these data highlight the need for additional
research to evaluate human health effects that
result in high levels of exposures to DEP,
DBP, BzBP, DEHP, and other phthalates.
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